Biontech plans to initiate the construction of an mrna vaccine manufacturing facility in africa in mid-2022

Mainz, germany, october 26, 2021 — biontech se (nasdaq: bntx, “biontech”) today announced that the company plans to initiate the construction of the first state-of-the-art manufacturing site for mrna-based vaccines in the african union in mid-2022. this is the next step in biontech's efforts to implement sustainable end-to-end vaccine supply solutions on the african continent. the decision is the result of a meeting between rwanda's minister of health, dr daniel m. ngamije, senegal's minister of foreign affairs aÏssata tall sall, ugur sahin, m.d.,ceo and co-founder of biontech and sierk poetting, coo of biontech as well as dr sabin nsanzimana, director-general of rwanda biomedical centre and dr amadou alpha sall, directeur-general of institut pasteur de dakar in kigali, rwanda. the meeting occurred upon the invitation of the kenup foundation and took place as a side-event of the second ministerial meeting of the african union and the european union and resulted in a memorandum of understanding (mou). this comes after the parties signed a joint communiquÉ at a previous meeting in berlin on august 27, 2021.
BNTX Ratings Summary
BNTX Quant Ranking